
S C Bain

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1686369/publications.pdf Version: 2024-02-01



S C RAIN

#	Article	IF	CITATIONS
1	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 1834-1844.	13.9	3,898
2	Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2019, 381, 841-851.	13.9	1,002
3	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet, The, 2017, 389, 1399-1409.	6.3	502
4	Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 251-260.	5.5	363
5	Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes and Endocrinology.the, 2017, 5, 355-366.	5.5	288
6	Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes, Obesity and Metabolism, 2018, 20, 889-897.	2.2	173
7	The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of TypeÂ2 Diabetes: The SURPASS Clinical Trials. Diabetes Therapy, 2021, 12, 143-157.	1.2	154
8	A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 3567-3602.	1.1	146
9	Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. Diabetes, Obesity and Metabolism, 2019, 21, 454-466.	2.2	129
10	Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes, Obesity and Metabolism, 2020, 22, 442-451.	2.2	102
11	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Diabetes Care, 2020, 43, 1546-1552.	4.3	92
12	Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation, 2022, 145, 575-585.	1.6	88
13	Anti-interleukin-21 antibody and liraglutide for the preservation of Î ² -cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 212-224.	5.5	85
14	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation, 2018, 138, 2884-2894.	1.6	82
15	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease. Circulation, 2018, 137, 2179-2183.	1.6	80
16	The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. Diabetes Care, 2018, 41, 2229-2235.	4.3	74
17	Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. Diabetes, Obesity and Metabolism, 2019, 21, 499-508.	2.2	71
18	Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovascular Diabetology, 2019, 18, 73.	2.7	69

#	Article	IF	CITATIONS
19	Large Pre- and Postexercise Rapid-Acting Insulin Reductions Preserve Glycemia and Prevent Early- but Not Late-Onset Hypoglycemia in Patients With Type 1 Diabetes. Diabetes Care, 2013, 36, 2217-2224.	4.3	66
20	A combined insulin reduction and carbohydrate feeding strategy 30Âmin before running best preserves blood glucose concentration after exercise through improved fuel oxidation in type 1 diabetes mellitus. Journal of Sports Sciences, 2011, 29, 279-289.	1.0	59
21	A Narrative Review of ChronicÂKidneyÂDisease in Clinical Practice: Current Challenges and Future Perspectives. Advances in Therapy, 2022, 39, 33-43.	1.3	57
22	Performance of the Freestyle Libre flash glucose monitoring (flash GM) system in individuals with type 1 diabetes: A secondary outcome analysis of a randomized crossover trial. Diabetes, Obesity and Metabolism, 2019, 21, 2505-2512.	2.2	55
23	Effects of Liraglutide on CardiovascularÂOutcomes in Patients With Diabetes With or Without HeartÂFailure. Journal of the American College of Cardiology, 2020, 75, 1128-1141.	1.2	53
24	One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. Journal of Diabetes and Its Complications, 2013, 27, 492-500.	1.2	42
25	LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. Cardiovascular Diabetology, 2016, 15, 29.	2.7	42
26	Blood glucose responses to reductions in pre-exercise rapid-acting insulin for 24Âh after running in individuals with type 1 diabetes. Journal of Sports Sciences, 2010, 28, 781-788.	1.0	41
27	Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events. JAMA Cardiology, 2019, 4, 1214.	3.0	39
28	Metabolic Implications when Employing Heavy Pre- and Post-Exercise Rapid-Acting Insulin Reductions to Prevent Hypoglycaemia in Type 1 Diabetes Patients: A Randomised Clinical Trial. PLoS ONE, 2014, 9, e97143.	1.1	38
29	Algorithm that delivers an individualized rapidâ€acting insulin dose after morning resistance exercise counters postâ€exercise hyperglycaemia in people with Type 1 diabetes. Diabetic Medicine, 2016, 33, 506-510.	1.2	36
30	Evaluation of the longâ€ŧerm costâ€effectiveness of onceâ€weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. Diabetes, Obesity and Metabolism, 2019, 21, 611-621.	2.2	35
31	Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. Annals of Internal Medicine, 2019, 170, 423.	2.0	34
32	Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme. Diabetes Therapy, 2020, 11, 259-277.	1.2	34
33	Impact of pre-exercise rapid-acting insulin reductions on ketogenesis following running in Type 1 diabetes. Diabetic Medicine, 2011, 28, 218-222.	1.2	33
34	Recent advances in understanding the role of glucagon-like peptide 1. F1000Research, 2020, 9, 239.	0.8	33
35	Effects of glucagonâ€like peptideâ€1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials. Diabetes, Obesity and Metabolism, 2020, 22, 2487-2492.	2.2	31
36	Similar magnitude of postâ€exercise hyperglycemia despite manipulating resistance exercise intensity in type 1 diabetes individuals. Scandinavian Journal of Medicine and Science in Sports, 2016, 26, 404-412.	1.3	30

#	Article	IF	CITATIONS
37	Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. Diabetes Care, 2021, 44, 1020-1026.	4.3	30
38	Exenatide and pancreatitis: an update. Expert Opinion on Drug Safety, 2008, 7, 643-644.	1.0	29
39	ADP-ribosylation factor 6 regulates endothelin-1-induced lipolysis in adipocytes. Biochemical Pharmacology, 2014, 90, 406-413.	2.0	27
40	Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK. Journal of Medical Economics, 2020, 23, 98-105.	1.0	27
41	The Effect of Clucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes. Diabetes Therapy, 2020, 11, 835-844.	1.2	27
42	IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy. Diabetes Therapy, 2015, 6, 573-591.	1.2	26
43	Costs of the <scp>COVID</scp> â€19 pandemic associated with obesity in Europe: A healthâ€care cost model. Clinical Obesity, 2021, 11, e12442.	1.1	26
44	Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. Circulation, 2018, 138, 1605-1607.	1.6	25
45	Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovascular Diabetology, 2020, 19, 156.	2.7	25
46	Association of British Clinical Diabetologists and Renal Association guidelines on the detection and management of diabetes post solid organ transplantation. Diabetic Medicine, 2021, 38, e14523.	1.2	25
47	The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist. Diabetes Therapy, 2014, 5, 367-383.	1.2	23
48	Similar risk of exerciseâ€related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized crossâ€over trial. Diabetes, Obesity and Metabolism, 2016, 18, 196-199.	2.2	23
49	Management of type 2 diabetes: <scp>t</scp> he current situation and key opportunities to improve care in the <scp>UK</scp> . Diabetes, Obesity and Metabolism, 2016, 18, 1157-1166.	2.2	22
50	Effect of structured selfâ€monitoring of blood glucose, with and without additional TeleCare support, on overall glycaemic control in nonâ€insulin treated Type 2 diabetes: the SMBG Study, a 12â€month randomized controlled trial. Diabetic Medicine, 2019, 36, 578-590.	1.2	22
51	Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. Diabetes, Obesity and Metabolism, 2019, 21, 1745-1751.	2.2	22
52	Costs of COVID-19 pandemic associated with diabetes in Europe: a health care cost model. Current Medical Research and Opinion, 2021, 37, 27-36.	0.9	20
53	Changes in Plasma Levels of N-Arachidonoyl Ethanolamine and N-Palmitoylethanolamine following Bariatric Surgery in Morbidly Obese Females with Impaired Glucose Homeostasis. Journal of Diabetes Research, 2015, 2015, 1-8.	1.0	19
54	Heart rate dynamics during cardio-pulmonary exercise testing are associated with glycemic control in in in individuals with type 1 diabetes. PLoS ONE, 2018, 13, e0194750.	1.1	19

#	Article	IF	CITATIONS
55	Impact of baseline characteristics and betaâ€cell function on the efficacy and safety of subcutaneous onceâ€weekly semaglutide: A patientâ€level, pooled analysis of the SUSTAIN 1â€5 trials. Diabetes, Obesity and Metabolism, 2020, 22, 303-314.	2.2	19
56	The effect of glucagonâ€like peptideâ€l receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials. Diabetes, Obesity and Metabolism, 2020, 22, 1690-1695.	2.2	19
57	Omarigliptin for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2016, 17, 1947-1952.	0.9	18
58	Semaglutide improves healthâ€related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (<scp>SUSTAIN</scp> 6). Diabetes, Obesity and Metabolism, 2020, 22, 1339-1347.	2.2	18
59	Safety and side effects of the insulin analogues. Expert Opinion on Drug Safety, 2006, 5, 131-143.	1.0	17
60	A multicentre, <scp>UK</scp> , retrospective, observational study to assess the effectiveness of insulin glargine 300 units/ml in treating people with Type 1 diabetes mellitus in routine clinical practice (<scp>SPARTA</scp>). Diabetic Medicine, 2019, 36, 110-119.	1.2	17
61	Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation. PLoS ONE, 2016, 11, e0154229.	1.1	17
62	Extent and prevalence of post-exercise and nocturnal hypoglycemia following peri-exercise bolus insulin adjustments in individuals with type 1 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 227-236.	1.1	16
63	Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study. Diabetes Therapy, 2021, 12, 801-811.	1.2	16
64	Poor glycaemic control is associated with reduced exercise performance and oxygen economy during cardio-pulmonary exercise testing in people with type 1 diabetes. Diabetology and Metabolic Syndrome, 2017, 9, 93.	1.2	14
65	<p>Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data</p> . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 433-438.	1.1	13
66	Self-monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes (The SMBG Study): study protocol for a randomised controlled trial. BMC Endocrine Disorders, 2017, 17, 4.	0.9	12
67	Supplementary Nitric Oxide Donors and Exercise as Potential Means to Improve Vascular Health in People with Type 1 Diabetes: Yes to NO?. Nutrients, 2019, 11, 1571.	1.7	12
68	The new NICE guidelines for type 2 diabetes – a critical analysis. British Journal of Diabetes and Vascular Disease, 2015, 15, 3.	0.6	12
69	Ageing well with diabetes: A workshop to coâ€design research recommendations for improving the diabetes care of older people. Diabetic Medicine, 2022, 39, e14795.	1.2	12
70	Resistance Isn't Futile: The Physiological Basis of the Health Effects of Resistance Exercise in Individuals With Type 1 Diabetes. Frontiers in Endocrinology, 2019, 10, 507.	1.5	11
71	Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 clinical trials. Diabetes, Obesity and Metabolism, 2020, 22, 2193-2198.	2.2	11
72	Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the <scp>LEADER</scp> randomized trial. Diabetes, Obesity and Metabolism, 2020, 22, 2077-2088.	2.2	10

#	Article	IF	CITATIONS
73	Safety of injectable semaglutide for type 2 diabetes. Expert Opinion on Drug Safety, 2020, 19, 785-798.	1.0	10
74	Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease. Diabetic Medicine, 2022, 39, e14769.	1.2	10
75	Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021. Kidney International Reports, 2022, 7, 681-687.	0.4	10
76	Recent developments in <scp>GLPâ€IRA</scp> therapy: A review of the latest evidence of efficacy and safety and differences within the class. Diabetes, Obesity and Metabolism, 2021, 23, 30-39.	2.2	9
77	Longâ€ŧerm efficacy and safety of combined insulin and glucagonâ€like peptideâ€1 therapy: Evidence from the LEADER trial. Diabetes, Obesity and Metabolism, 2019, 21, 2450-2458.	2.2	8
78	Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK. Diabetic Medicine, 2019, 36, 1063-1071.	1.2	8
79	Semaglutide injection for the treatment of adults with type 2 diabetes. Expert Review of Clinical Pharmacology, 2020, 13, 675-684.	1.3	8
80	Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. Cardiovascular Endocrinology, 2018, 7, 18-23.	0.8	7
81	Treatment of Type 2 Diabetes Mellitus With Orally Administered Agents: Advances in Combination Therapy. Endocrine Practice, 2009, 15, 750-762.	1.1	5
82	Diabetes, diabetes therapies and cancer: what's the link?. British Journal of Diabetes and Vascular Disease, 2011, 11, 235-238.	0.6	5
83	A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes. Diabetic Medicine, 2020, 37, 219-228.	1.2	5
84	Clinical experience with liraglutide. International Journal of Clinical Practice, 2010, 64, 44-48.	0.8	4
85	A retrospective observational study of people with Type 1 diabetes with selfâ€reported severe hypoglycaemia reveals high level of ambulance attendance but low levels of therapy change and specialist intervention. Diabetic Medicine, 2018, 35, 1223-1231.	1.2	4
86	Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2018, 12, 1079-1082.	1.8	4
87	SaOO10EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	4
88	FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) – A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	4
89	Delivering joined-up care for people with type 2 diabetes: rationale, challenges and examples. British Journal of Diabetes, 2021, 21, 89-95.	0.1	4
90	Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A populationâ€based observational retrospective cohort study. Diabetic Medicine, 2022, 39, e14697.	1.2	4

#	Article	IF	CITATIONS
91	Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice. Diabetes Therapy, 2022, 13, 225-240.	1.2	4
92	New Therapeutic Horizons in ChronicÂKidneyÂDisease: The Role of SGLT2 Inhibitors in Clinical Practice. Drugs, 2022, 82, 97-108.	4.9	4
93	Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6. Cardiovascular Diabetology, 2022, 21, 64.	2.7	4
94	Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity. , 2022, 18, 43.		4
95	FP482EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	3
96	Efficacy of newer agents in the glycaemic management of patients with type 2 diabetes. Current Medical Research and Opinion, 2020, 36, 209-211.	0.9	3
97	Metabolomic, hormonal and physiological responses to hypoglycemia versus euglycemia during exercise in adults with type 1 diabetes. BMJ Open Diabetes Research and Care, 2020, 8, e001577.	1.2	3
98	Estimands in diabetes clinical trials. Lancet Diabetes and Endocrinology,the, 2020, 8, 181-183.	5.5	3
99	One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus. Diabetes Therapy, 2021, 12, 1593-1604.	1.2	3
100	A retrospective epidemiological study of Type 1 Diabetes Mellitus in Wales, UK between 2008 and 2018. International Journal of Population Data Science, 2021, 6, 1387.	0.1	3
101	The Cellnovo Insulin Delivery System. European Endocrinology, 2017, 13, 13.	0.8	3
102	Blood Glucose Responses during Cardiopulmonary Incremental Exercise Testing in Type 1 Diabetes: A Pooled Analysis. Medicine and Science in Sports and Exercise, 2021, 53, 1142-1150.	0.2	3
103	Postmarket Approval Surveillance of a Low Acquisition Cost Blood Glucose Monitoring System. Journal of Diabetes Science and Technology, 2016, 10, 1195-1196.	1.3	2
104	A case series of DKA occurring in patients receiving treatment with SGLTâ€2 inhibitors. Diabetes, Obesity and Metabolism, 2018, 20, 1800-1801.	2.2	2
105	MO051EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	2
106	TO002REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	2
107	Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. Drugs, 2021, 81, 1243-1255.	4.9	2
108	Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently. Diabetes Therapy, 2022, 13, 889-911.	1.2	2

#	Article	IF	CITATIONS
109	Basal insulin reductions in anticipation of multiple exercise sessions in people with type 1 diabetes—a clinical perspective. Annals of Translational Medicine, 2018, 6, S111-S111.	0.7	1
110	Pancreatic β-Cell Function Is Associated with Augmented Counterregulation to In-Exercise Hypoglycemia in Type 1 Diabetes. Medicine and Science in Sports and Exercise, 2021, 53, 1326-1333.	0.2	1
111	Complex disease genetics enters the high street. European Journal of Clinical Investigation, 2003, 33, 186-188.	1.7	0
112	Safety and side effects of the insulin analogues. Expert Opinion on Drug Safety, 2006, 5, 349-350.	1.0	0
113	Liraglutide in Combination with Metformin or Sulfonylurea for the Treatment of Type 2 Diabetes in Adult patients. Clinical Medicine Insights Therapeutics, 2012, 4, CMT.S7283.	0.4	0
114	P6271The effect of semaglutide once weekly on MACE and blood pressure by race and ethnicity: SUSTAIN 6 post hoc analysis. European Heart Journal, 2019, 40, .	1.0	0
115	Clumsy hands in a woman with longâ€standing diabetes. Diabetic Medicine, 2019, 37, 1770-1771.	1.2	0
116	An unusual finding during retinal screening. Diabetic Medicine, 2020, 37, 1605-1606.	1.2	0
117	Foot deformity in a man with Type 2 diabetes. Diabetic Medicine, 2020, 37, 157-158.	1.2	0
118	An update to: Pharmacological treatment for type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK . Diabet Med 2019; 36: 1063–1071. Diabetic Medicine, 2020, 37, 1405-1407.	1.2	0
119	A slightly itchy rash on the hand of a person with type 1 diabetes. Diabetic Medicine, 2020, 37, 1609-1610.	1.2	0
120	An unusual skin rash in a person with type 1 diabetes. Diabetic Medicine, 2020, 37, 1607-1608.	1.2	0
121	A man with nodules on the backs of his hands. Diabetic Medicine, 2020, 37, 1766-1767.	1.2	0
122	Cover Image, Volume 22, Issue 3. Diabetes, Obesity and Metabolism, 2020, 22, .	2.2	0
123	Improved Nocturnal Glycaemia and Reduced Insulin Use Following Clinical Exercise Trial Participation in Individuals With Type 1 Diabetes. Frontiers in Public Health, 2020, 8, 568832.	1.3	0
124	A woman with poorly controlled type 1 diabetes and pruritic papules on her buttocks. Diabetic Medicine, 2021, 38, e14539.	1.2	0
125	Semaglutid reduzierte den HbA1c in allen Subgruppen des Ausgangs-HbA1c (SUSTAIN 1 – 5). Diabetologie Und Stoffwechsel, 2018, 13, .	0.0	0
	Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of		

¹²⁶ baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme. , 2019, 14, .

#	Article	IF	CITATIONS
127	An elderly woman with scars on her shins. Diabetic Medicine, 2022, 39, e14818.	1.2	Ο
128	MO462: Change in KDIGO Kidney Risk Category With Semaglutide Treatment—A <i>Post Hoc</i> Analysis of the Sustain 6 Trial. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
129	Glucagon-like peptide-1 receptor agonists as anti-inflammatory agents: A potential mode of cardiovascular benefits. Atherosclerosis, 2022, , .	0.4	Ο